Combination Therapy with STAT3 Inhibitor Enhances SERCA2a-Induced BMPR2 Expression and Inhibits Pulmonary Arterial Hypertension

Combination Therapy with STAT3 Inhibitor Enhances SERCA2a-Induced BMPR2 Expression and Inhibits Pulmonary Arterial Hypertension

Pulmonary arterial hypertension (PAH) is a devastating lung disease characterized by the progressive obstruction of the distal pulmonary arteries (PA). Structural and functional alteration of pulmonary artery smooth muscle cells (PASMC) and endothelial cells (PAEC) contributes to PA wall remodeling...

Full description

Bibliographic Details
Main Authors: Malik Bisserier, Michael G. Katz, Carlos Bueno-Beti, Agnieszka Brojakowska, Shihong Zhang, Sarah Gubara, Erik Kohlbrenner, Shahood Fazal, Anthony Fargnoli, Peter Dorfmuller, Marc Humbert, Akiko Hata, David A. Goukassian, Yassine Sassi, Lahouaria Hadri
Format: Article
Language:English
Published: MDPI AG 2021-08-01
Series:International Journal of Molecular Sciences
Subjects:
gene therapy
pulmonary arterial hypertension
right heart failure
BMPR2
SERCA2a
STAT3
Online Access:https://www.mdpi.com/1422-0067/22/17/9105

Internet

https://www.mdpi.com/1422-0067/22/17/9105

Similar Items